Tabimorelin
Orally active GH secretagogue from early clinical research.
Evidence
anecdotal
Legal status
research only
Half-life
Medium (~half-day)
Routes
oral
What it is
Orally active GH secretagogue from early clinical research.
Mechanism
Orally active GH secretagogue from early clinical research.
Outcomes it's matched to
- STRENGTH70%
Safety
Educational reference only. Long-term human safety varies; consult a peptide-literate clinician.
Legal context
Investigational